- Conditions
- Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
- Interventions
- Zanubrutinib
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 1,303
matching trials from the live ClinicalTrials.gov search.
- Conditions
- High-risk Diffuse Large B-Cell Lymphoma
- Interventions
- Blinatumomab, Investigator's Choice Chemotherapy, Dexamethasone
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Maywood, Illinois • New Orleans, Louisiana + 5 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Venetoclax, Obinutuzumab, Rituximab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Small Lymphocytic Lymphoma
- Interventions
- romidepsin, rituximab, fludarabine phosphate, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Lymphoma
- Interventions
- Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diffuse Large B-cell Lymphoma, Follicle Center Lymphoma
- Interventions
- Zevalin, Y-90-Zevalin, Rituximab, In-111 Zevalin
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 28
- States / cities
- Casa Grande, Arizona • Berkeley, California • Duarte, California + 24 more
- Conditions
- Lymphoma, B-Cell
- Interventions
- Rituximab, Ifosfamide, Carboplatin, Etoposide, Bortezomib
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Graft vs Host Disease, Alogenic Hematopoietic Transplant
- Interventions
- Rituximab
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Lymphoma, Follicular
- Interventions
- Ofatumumab, Bendamustine infusion, Ofatumumab and Bendamustine infusions (Arm A), Bendamustine infusion (Arm B)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • Beverly Hills, California • Palm Springs, California + 15 more
- Conditions
- Lymphoma, Low-Grade, Lymphoma, Small Lymphocytic, Lymphoma, Mixed-Cell, Follicular, Lymphoma, Small Cleaved-Cell, Follicular
- Interventions
- Pixantrone (BBR 2778), fludarabine, dexamethasone, rituximab
- Drug
- Lead sponsor
- CTI BioPharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Baltimore, Maryland • Albuquerque, New Mexico + 1 more
- Conditions
- Pemphigus Vulgaris
- Interventions
- Mycophenolate Mofetil Placebo, Mycophenolate Mofetil, Rituximab, Rituximab Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 12 more
- Conditions
- Lymphoma, Primary Central Nervous System Lymphoma
- Interventions
- Pembrolizumab, Methotrexate, Temozolomide, Rituximab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Lymphoma, Small Lymphocytic, Leukemia, Lymphocytic, Chronic
- Interventions
- cenersen sodium, Rituximab, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- David Rizzieri
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Recombinant Human Interleukin-2 and Rituximab
- Drug
- Lead sponsor
- Chiron Corporation
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 33
- States / cities
- Tucson, Arizona • Newport Beach, California • Sacramento, California + 28 more
- Conditions
- Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
- Interventions
- DCDT2980S, rituximab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 9
- States / cities
- Stanford, California • Denver, Colorado • Washington D.C., District of Columbia + 5 more
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- Revlimid
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 2
- States / cities
- Hackensack, New Jersey • Durham, North Carolina
- Conditions
- B-Cell Lymphoma
- Interventions
- inotuzumab ozogamicin, Rituximab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Greenbrae, California • San Francisco, California + 11 more
- Conditions
- Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia
- Interventions
- Cladribine, Laboratory Biomarker Analysis, Rituximab
- Drug · Other · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Follicular Lymphoma
- Interventions
- Combination of treatment modalities
- Other
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Lymphoma
- Interventions
- Duvelisib, Rituximab, R-CHOP, Prednisone
- Drug
- Lead sponsor
- SecuraBio
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Zanubrutinib, Rituximab, Patient Observation, Bone Marrow Biopsy, Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging, Esophagogastroduodenoscopy, Colonoscopy, Biospecimen Collection, Questionnaire Administration
- Drug · Biological · Other + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 421 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2038
- U.S. locations
- 238
- States / cities
- Little Rock, Arkansas • Beverly Hills, California • Duarte, California + 185 more
- Conditions
- Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
- Interventions
- Copanlisib, Gemcitabine, Carboplatin, Dexamethasone, Rituximab, Pegfilgrastim
- Drug · Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Lymphoma
- Interventions
- Rituximab, GM-CSF
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Diffuse Large B-Cell Lymphoma Unclassifiable, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma
- Interventions
- Carboplatin, Etoposide, Ifosfamide, Polatuzumab Vedotin, Rituximab
- Drug · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Duarte, California • Atlanta, Georgia